PTO/SB/96 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Genentech, Inc.	
Application No./Patent No.: 6,998,253 Filed/Issu	e Date:February 14, 2006
Entitled: ALTERED POLYPEPTIDES WITH INCREASED HALF-LIFE	
Genentech Inc. , a (Type of Assignee, e.g., co	corporation
(Name of Assignee) (Type of Assignee, e.g., or	orporation, partnership, university, government agency, etc.)
states that it is:	
1. x the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest.	
(The extent (by percentage) of its ownership interest is	
in the patent application/patent identified above by virtue of either:	
A. X An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therof is attached.	
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:	
1. From: To:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
2. From: To:	
The document was recorded in the United States Patent	
Reel , Frame , or for wh	
	and Trademonts Office at
The document was recorded in the United States Patent a Reel . Frame . or for wh	
Reel, Frame, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet.	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO.	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
/Terri Shieh-Newton/	January 7, 2008
Signature	Date
Terri Shieh-Newton	(650) 813-5777
Printed or Typed Name	Telephone Number
Attorney of Record for Assignee Title	
THO	

Attorney Docket No.: 146392001607

ASSIGNMENT

WHEREAS, Leonard G. Presta, a citizen of the USA, residing at 1900 Gough Street, Apt. 206, San Francisco, CA 94109, and Bradley R. Snedecor, a citizen of USA, residing at 310 Gabarda Way, Portola Valley, CA 94028 (hereinafter "ASSIGNORS"), have invented a new and useful invention in

ALTERED POLYPEPTIDES WITH INCREASED HALF-LIFE

for which an application Serial No. (Docket No. PO932) for Letters Patent has been filed by them on 14 April 1995; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 460 Point San Bruno Boulevard, South San Francisco, California 94080, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco, CA

Dated: April 13, 1995

South San Francisco, CA

Dated: April 12, 1995